Award
National Institute of Allergy and Infectious Diseases 2R01AI150091-06A1
A Novel Prime/Pull/Keep mRNA-Based Vaccine to Prevent Recurrent Genital Herpes
Recipient
University of California-Irvine
Award Amount
$784,998.00
Ceiling
$784,998.00
Awarded
June 01, 2026
Identifier
2R01AI150091-06A1
This award funds research to develop a novel mRNA-based vaccine aimed at preventing recurrent genital herpes by enhancing tissue-resident T cell immunity. The project includes preclinical testing in guinea pigs and focuses on a Prime/Pull/Keep immunotherapeutic approach to achieve long-lasting protection.
Description
Development of a mRNA-based therapeutic vaccine to induce long-lasting protection against recurrent genital herpes by boosting tissue-resident T cells in neural and mucosal tissues. The project involves preclinical studies in guinea pigs and aims to evaluate the safety and efficacy of a Prime/Pull/Keep (PPK) vaccine strategy.